EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib - Yoshimura, N; Kudoh, S; Kimura, T (Lung Cancer, 2006)
et al.